Membrane Protein Monoclonal AntibodiesGenetic Engineering NewsTherapeutic antibodies are a key driving force in the biotechnology industry thanks to their ability to safely and effectively target a broad range of diseases, including cancer, autoimmune …
1 Department of Medical Radiation Physics, Lund University, Lund, SwedenJournal of Nuclear Medicine (subscription)The aim of this study was to investigate the distribution of 177Lu-DOTA-BR96 monoclonal antibodies targeting the Lewis Y antigen over 7 d …
Therapy for severe vasculitis shows long-term effectivenessNational Institutes of Health (press release)Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with…
|
TrialShare portal strikes blow for data transparency
PharmaTimes … is debuting its TrialShare portal in conjunction with the publication in the New England Journal of Medicine of 18-month results from the Network’s RAVE trial of the B-cell depleting agent rituximab in Wegener’s Granulomatosis and Microscopic … |
NIH-funded study finds that rituximab is as effective as standard therapy for …News-Medical.netAdministering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe…
|
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Ulcerative Colitis
PipelineReview.com (press release) LEIDEN, The Netherlands I July 26, 2013 I Janssen Biologics B.V. (“Janssen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use … |
The IN VIVO Blog (blog) |
Deals Of the Week, Once Again, Ponders Biosimilars
The IN VIVO Blog (blog) Like their competitors, Teva and Lonza held much of their work close to their vests, but they had counted on developing a franchise around a biosimilar version of Roche’s $7 billion Rituxan (rituximab) franchise, only to halt clinical development last … |
|
AbbVie Inc. (ABBV) CEO Discusses Q2 2013 Results – Earnings Call Transcript
Seeking Alpha Daclizumab, currently in Phase III development in partnership with Biogen for multiple sclerosis – our second pivotal study will read out next year and we’re planning global registration submissions in 2014 as well. Elagolix is being evaluated in Phase … |
Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common …Journal of VirologyInteractions between viruses and the host antibody immune response are critical in the development and control of disease, and antibodies are also known t…
|
Oral steroid-free maintenance therapy effective in most patients with lupus …
Healio Using a steroid-avoiding “rituxilup” protocol, researchers in London reported the outcomes of 50 patients (median age, 45 years; 39 women) with active lupus nephritis who received two doses of rituximab (1 g) and methylprednisolone (500 mg) on days 1 … |